Optinose IPO

Optinose Announces Pricing of Initial Public Offering

Yardley, PA, Oct. 12, 2017 — OptiNose, Inc. (Optinose), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts, for total gross proceeds of $120,000,000. All of the shares are being offered by Optinose. In addition, Optinose has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discount. The shares are scheduled to begin trading on the NASDAQ Global Select Market under the ticker symbol “OPTN” on Friday, October 13, 2017. The offering is expected to close on October 17, 2017, subject to the satisfaction of customary closing conditions.

View full press release here